The Priority Review

Tag

Ramantamig

1 story

Stories

  1. Clinical trials

    Janssen registers Ramantamig and Daratumumab versus DVRd trial in newly diagnosed multiple myeloma

    The study, led by Janssen Research & Development, LLC, plans to enroll 1000 participants and is scheduled to start on December 14, 2026. It compares Ramantamig plus Daratumumab with the standard DVRd regimen followed by high-dose therapy, autologous stem cell transplant, and maintenance therapy.